There is a window of time in humans, hypothesized as preclinical Alzheimer's disease (AD) during which amyloid-? (A?) deposition and tauopathy accrues prior to the detection of clinical symptoms and signs of cognitive impairment. By the time of clinical detection of symptomatic AD, there is already significant cell and synaptic loss. An important goal is to determine whether there are changes not only in imaging and fluid biomarkers, but also in brain function, that are associated with preclinical AD that are 1) quantitative;2) predict prognosis;and 3) respond to therapeutic intervention. Sleep in an essential biological function that becomes significantly abnormal during the course of dementia due to AD. We have shown that soluble, monomeric A? in both mice and humans is regulated by the sleep/wake cycle. We have also found that as APP transgenic mice develop A? deposition, sleep, particularly non-REM sleep, is markedly disrupted and that this is secondary to A? accumulation. We have also assessed sleep in a mouse model of tauopathy (P301S Tau transgenic mice) and have noted a marked decline in delta power during non-REM sleep. In recent studies, we have assessed sleep in a cohort of late-middle aged individuals with actigraphy, and found that those with A? deposition have significantly decreased sleep efficiency (% of time sleeping while in bed). Very few of the individuals in our first study had developed neurodegeneration (e.g. increased CSF tau) and we did not assess sleep stages directly by EEG. Herein, we will assess a cohort of individuals who are somewhat older (with mean age ~75);many are cognitively normal with and without different stages of preclinical AD and some have very mild dementia. We hypothesize that decreases in non-REM sleep and delta power will begin during the initial phases of A? deposition and worsen with biomarker evidence of neurodegeneration and tauopathy during preclinical AD and mild cognitive impairment (MCI). In addition, we hypothesize that changes in sleep detected initially and longitudinally will be quantitative diagnostic and prognostic markers of brain injury that have potential to respond to therapeutic intervention (theranostic markers). We predict that progressive changes in sleep will correlate with brain atrophy and dysfunction as assessed by structural MRI, functional connectivity MRI, and certain aspects of longitudinal cognitive performance such as the practice effect.

Public Health Relevance

As instructed by the funding opportunity announcement for this application (PAR-13-329), only the Overall component contains a project narrative. Cores and projects were instructed not to include this section.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Saint Louis
United States
Zip Code
Adel, Tameem; Cohen, Taco; Caan, Matthan et al. (2017) 3D scattering transforms for disease classification in neuroimaging. Neuroimage Clin 14:506-517
Schindler, Suzanne E; Jasielec, Mateusz S; Weng, Hua et al. (2017) Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. Neurobiol Aging 56:25-32
Zhao, Yue; Raichle, Marcus E; Wen, Jie et al. (2017) In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. Neuroimage 148:296-304
Su, Yi; Vlassenko, Andrei G; Couture, Lars E et al. (2017) Quantitative hemodynamic PET imaging using image-derived arterial input function and a PET/MR hybrid scanner. J Cereb Blood Flow Metab 37:1435-1446
Deming, Yuetiva; Li, Zeran; Kapoor, Manav et al. (2017) Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. Acta Neuropathol 133:839-856
Day, Gregory S; Lim, Tae Sung; Hassenstab, Jason et al. (2017) Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology 88:1273-1281
Monsell, Sarah E; Mock, Charles; Fardo, David W et al. (2017) Genetic Comparison of Symptomatic and Asymptomatic Persons With Alzheimer Disease Neuropathology. Alzheimer Dis Assoc Disord 31:232-238
Mez, Jesse; Chung, Jaeyoon; Jun, Gyungah et al. (2017) Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans. Alzheimers Dement 13:119-129
Khajehnejad, Moein; Saatlou, Forough Habibollahi; Mohammadzade, Hoda (2017) Alzheimer's Disease Early Diagnosis Using Manifold-Based Semi-Supervised Learning. Brain Sci 7:
Holth, Jerrah; Patel, Tirth; Holtzman, David M (2017) Sleep in Alzheimer's Disease - Beyond Amyloid. Neurobiol Sleep Circadian Rhythms 2:4-14

Showing the most recent 10 out of 831 publications